Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
AssigneeBeijing Cotimes Biotech Co., Ltd.
InventorsEnyun Shen, Yang Song, Shiqi Ren
Life of this patent
Estimating the term…
Abstract
The present invention provides uses of cytokeratins as markers for diagnosing epithelium derived cancers. The present invention provides caner-related epitopes of cytokeratins and monoclonal antibodies which specifically recognize the epitopes. The present invention also provides methods for the early screen, diagnosis or prognosis of epithelium derived cancers in subjects, methods for the evaluation of therapeutic effect of related medicaments or therapies, and kits for accomplishing the methods.
Claims21
-21. (canceled)
A monoclonal antibody that specifically binds to an epithelium-derived cancer-related cytokeratin fragment, wherein the fragment comprises one or more epitopes selected from the group consisting of SEQ ID NOs:
- 2, 3, 5 and 6.
A method of determining a diagnosis or prognosis of cancer in a subject, comprising contacting a biological sample from the subject with a monoclonal antibody that specifically binds to an epithelium-derived cancer-related cytokeratin fragment, wherein the fragment comprises one or more epitopes selected from the group consisting of SEQ ID NOs:
- 2, 3, 5 and 6.
A kit for determining a diagnosis or prognosis of cancer, comprising a monoclonal antibody that specifically binds an epithelium-derived cancer-related cytokeratin fragment, wherein the fragment comprises one or more epitopes selected from the group consisting of SEQ ID NOs:
- 2, 3, 5 and 6.
A hybridoma cell line having a deposit number selected from the group consisting of CGMCC 1957, CGMCC 1956, CGMCC 1955, and CGMCC 1952.
Dependencies are inferred from the claim text.